<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257162</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1804</org_study_id>
    <secondary_id>2019-002991-15</secondary_id>
    <nct_id>NCT04257162</nct_id>
  </id_info>
  <brief_title>HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)</brief_title>
  <acronym>HER2-PREDICT</acronym>
  <official_title>HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HER2-Predict is a multi-center, observational study using biological samples from patients&#xD;
      treated with DS-8201a in the metastatic setting. Patients will provide a baseline FFPE tumor&#xD;
      sample and additionally, blood sample for ctDNA determination will be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>identify the optimal ERBB2 mRNA cut-point predictive of T-DXd response</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor and Blood sample collection</intervention_name>
    <description>This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.&#xD;
Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.&#xD;
Tumor sample and blood sample will be collected within the framework of HER2-Predict Study</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A. Inclusion Criteria&#xD;
&#xD;
          1. Women and men ≥18 years old that has been included in a trial using Trastuzumab&#xD;
             Deruxtecan (T-DXd; DS-8201a).&#xD;
&#xD;
          2. The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the study. It is possible to include patients that were exitus&#xD;
             during or after treatment by filling out the appendix 1 form and filing it into the&#xD;
             patient's clinical chart.&#xD;
&#xD;
          3. Patients who are starting, are receiving or have received treatment with Trastuzumab&#xD;
             Deruxtecan as a treatment for metastatic/advanced cancer.&#xD;
&#xD;
          4. Submission of a formalin-fixed, paraffin-embedded tumor (FFPE) tissue block from the&#xD;
             most recently collected tumor tissue, with an associated pathology report, for central&#xD;
             molecular analysis and for other protocol-mandated secondary and exploratory&#xD;
             assessments. If a newer specimen is either insufficient or unavailable, the patient&#xD;
             may still be eligible if the patient can provide a tissue block (preferred) or is&#xD;
             willing to consent to and undergo an additional pretreatment core or excisional biopsy&#xD;
             (if it is assessable and the biopsy can be safely obtained). The tumor tissue should&#xD;
             be of good quality and quantity based on total and viable tumor content.&#xD;
&#xD;
               1. Acceptable samples include core needle biopsies of the deep metastatic lesion or&#xD;
                  excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous,&#xD;
                  or mucosal lesions or biopsies from bone metastases.&#xD;
&#xD;
               2. Fine needle aspiration, brushing, cell pellet from pleural effusion and lavage&#xD;
                  samples are not acceptable.&#xD;
&#xD;
          5. Patients included before starting experimental treatment must be able and willing to&#xD;
             provide blood sample(s).&#xD;
&#xD;
             B. Exclusion Criteria&#xD;
&#xD;
          6. Not having participated or not willing to participate in a trial using Trastuzumab&#xD;
             Deruxtecan.&#xD;
&#xD;
          7. Inability to comply with study and follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jordi Canes Ruiz</last_name>
    <phone>933436302</phone>
    <email>jordi.canes@gruposolti.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vanesa Quiroga Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>Cadiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rubén del Toro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josefina Cruz Jurado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Servitja Tormo Sonia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleix Prat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Saura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sonia Pernas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.Univ. Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Serafín Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pilar Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Ciruelos</last_name>
    </contact>
    <investigator>
      <last_name>Eva Ciruelos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Jose Bermejo Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jerónimo Martínez</last_name>
      <phone>+34 968 36 93 87</phone>
      <email>jeronimo@seom.org</email>
    </contact>
    <investigator>
      <last_name>Jerónimo Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Salvador Bofill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Esteban Nogales Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología (IVO)</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Mallol Roselló</last_name>
      <email>coordinacion@fincivo.org</email>
    </contact>
    <investigator>
      <last_name>Joaquin Gavilà Gregori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

